Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 9, Number 12—December 2003

Dispatch

Visceral Leishmaniasis Treatment, Italy

Luigi Gradoni*Comments to Author , Marina Gramiccia*, and Aldo Scalone*
Author affiliations: *Istituto Superiore di Sanità, Rome, Italy

Main Article

Table

First-line drugs used for treatment of visceral leishmaniasis in 533 immunocompetent patients in Italy and drug treatment failures recordeda

Y MA (%) L-AmB ABCD ABLC dAmB Any AmB drugs (%)
1995
57 (55.9)
3 R
45
1 R
0
0
0
45 (44.1)
1 R
1996
35 (50.0)
2 R
35
1 R
0
0
0
35 (50.0)
1 R
1997
26 (39.4)
3 U, 1 R
34
2 R
5
0
1
40 (60.6)
2 R
1998
14 (28.0)
1 R
32
1 R
4
0
0
36 (72.0)
1 R
1999
13 (21.0)
1 U, 1 R
45
2 R
2
1
1
49 (79.0)
2 R
2000
11 (9.8)
1 U, 3 R
89
1 U, 1 R
10
1 U
1
1 R
1
101 (90.2)
2 U, 2 R
2001
2 (2.8)
68
1 R
0
1
0
69 (97.2)
1 R
Total 158 (29.6) 5 U, 11 R 348
1 U, 9 R 21
1 U 3
1 R 3 375 (70.4)
2 U, 10 R

aMA, meglumine antimoniate; L-AmB, liposomal amphotericin B; ABCD, amphotericin B colloidal dispersion; ABLC, amphotericin B lipid complex; dAmB, amphotericin B desoxycholate; U, unresponsiveness and/or acute toxicity; R, relapse.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO